Page 52 - IMO-2-2
P. 52

Innovative Medicines & Omics                                           Alzheimer’s disease and clinical trials



               doi: 10.1016/j.jpha.2021.06.001                 70.  Palmer AM. Neuroprotective therapeutics for Alzheimer’s
                                                                  disease: Progress and prospects.  Trends Pharmacol Sci.
            59.  Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA,
               Cummings JL. Alzheimer’s disease.  Nat Rev Dis Primers.   2011;32:141-147.
               2015;1:15056.                                      doi: 10.1016/j.tips.2010.12.007
               doi: 10.1038/nrdp.2015.56                       71.  Tonnies E, Trushina E. Oxidative stress, synaptic
                                                                  dysfunction, and Alzheimer’s  disease.  J  Alzheimers  Dis.
            60.  Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s
               disease at 25 years. EMBO Mol Med. 2016;8:595-608.  2017;57:1105-1121.
                                                                  doi: 10.3233/JAD-161088
               doi: 10.15252/emmm.201606210
                                                               72.  Choi SH, Tanzi RE. Is Alzheimer’s disease a neurogenesis
            61.  Kametani F, Hasegawa M. Reconsideration of amyloid
               hypothesis and tau hypothesis in Alzheimer’s disease. Front   disorder? Cell Stem Cell. 2019;25:7-8.
               Neurosci. 2018;12:25.                              doi: 10.1016/j.stem.2019.06.001
               doi: 10.3389/fnins.2018.00025                   73.  Sampaio TB, Savall AS, Gutierrez MEZ, Pinton S.
                                                                  Neurotrophic factors in Alzheimer’s and Parkinson’s
            62.  Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T.
               Invited review: APOE at the interface of inflammation,   diseases: Implications for pathogenesis and therapy. Neural
               neurodegeneration and pathological protein spread   Regen Res. 2017;12:549-557.
               in Alzheimer’s disease.  Neuropathol Appl Neurobiol.      doi: 10.4103/1673-5374.205084
               2019;45:327-346.
                                                               74.  Pike  CJ.  Sex  and  the  development of  Alzheimer’s  disease.
               doi: 10.1111/nan.12529                             J Neurosci Res. 2017;95:671-680.
            63.  Xue-Shan Z, Juan P, Qi W,  et al. Imbalanced cholesterol      doi: 10.1002/jnr.23827
               metabolism in Alzheimer’s disease.  Clin Chim Acta.   75.  Gold M. Phase II clinical trials of anti-amyloid β antibodies:
               2016;456:107-114.
                                                                  When is enough, enough?  Alzheimers Dement  (N Y).
               doi: 10.1016/j.cca.2016.02.024                     2017;3:402-409.
            64.  Calsolaro V, Edison P. Alterations in glucose metabolism in      doi: 10.1016/j.trci.2017.04.005
               Alzheimer’s disease. Recent Pat Endocr Metab Immune Drug   76.  Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G.
               Discov. 2016;10:31-39.
                                                                  Preliminary results of a trial of atabecestat in preclinical
               doi: 10.2174/1872214810666160615102809             Alzheimer’s disease. N Engl J Med. 2019;380:1483-1485.
            65.  Ninomiya T. Epidemiological evidence of the relationship      doi: 10.1056/NEJMc1813435
               between diabetes and dementia.  Adv Exp Med Biol.   77.  Lilly E.  Lilly Announces Topline Results for Solanezumab
               2019;1128:13-25.
                                                                  from the Dominantly Inherited Alzheimer Network Trials
               doi: 10.1007/978-981-13-3540-2_2                   Unit (DIAN-TU) Study. 2020.

            66.  Shieh JC, Huang PT, Lin YF. Alzheimer’s disease and diabetes:   78.  Cummings J. Lessons learned from Alzheimer disease:
               Insulin signaling as the bridge linking two pathologies. Mol   Clinical trials with negative outcomes.  Clin Transl Sci.
               Neurobiol. 2020;57:1966-1977.                      2018;11:147-152.
               doi: 10.1007/s12035-019-01858-5                    doi: 10.1111/cts.12491
            67.  Arvanitakis Z, Tatavarthy M, Bennett DA. The relation   79.  Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials
               of diabetes to memory function.  Curr Neurol Neurosci   for Alzheimer’s disease drugs keep failing? A discontinued
               Rep. 2020;20:64.                                   drug perspective for 2010-2015. Expert Opin Investig Drugs.
                                                                  2017;26:735-739.
               doi: 10.1007/s11910-020-01085-9
                                                                  doi: 10.1080/13543784.2017.1323868
            68.  Gabin JM, Tambs K, Saltvedt I, Sund E, Holmen J. Association
               between blood pressure and Alzheimer disease measured up   80.  Arndt JW, Qian F, Smith BA, et al. Structural and kinetic
               to 27 years prior to diagnosis: The HUNT Study. Alzheimers   basis for the selectivity of aducanumab for aggregated forms
               Res Ther. 2017;9:37.                               of amyloid-β. Sci Rep. 2018;8:6412.
               doi: 10.1186/s13195-017-0262-x                     doi: 10.1038/s41598-018-24501-0
            69.  Nunomura  A,  Perry  G.  RNA  and oxidative  stress  in   81.  Sevigny J, Chiao P, Bussiere T,  et al. The antibody
               Alzheimer’s disease: Focus on microRNAs. Oxid Med Cell   aducanumab reduces Aβ plaques in Alzheimer’s disease.
               Longev. 2020;2020:2638130.                         Nature. 2016;537:50-56.
               doi: 10.1155/2020/2638130                          doi: 10.1038/nature19323


            Volume 2 Issue 2 (2025)                         46                          doi: 10.36922/IMO025050007
   47   48   49   50   51   52   53   54   55   56   57